Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03000998
Other study ID # 0310
Secondary ID 1R01CA210125-01A
Status Completed
Phase N/A
First received
Last updated
Start date January 31, 2017
Est. completion date June 30, 2022

Study information

Verified date February 2023
Source Klein Buendel, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The uptake of vaccines for Human Papillomavirus (HPV) in the U.S. is far below recommended levels, particularly for adolescent boys and especially among minority families. Proposed here is a mobile web application ("mobile web app") for personal computers, smart phones, and tablet computers that will accurately inform parents and adolescent boys about the HPV vaccination and address unique concerns about its safety and effectiveness for boys. The BoyVac mobile web app will be evaluated for its ability to improve vaccine outcomes in a randomized efficacy trial with parents and adolescent boys aged 11-13 years.


Description:

The President's Cancer Advisory Board and the Centers for Disease Control have called for renewed efforts in promoting vaccination for Human Papillomavirus (HPV), including vaccination for adolescent boys, because the uptake of this new vaccine remains alarmingly low. Currently, less than 15% of adolescent boys have received the HPV vaccine; thus, most of this population remains at risk for oropharyngeal, anal, and penile cancers. Many parents remain unconvinced of the safety and effectiveness of HPV vaccines, so effective and accessible messaging to improve decision-making on this vaccine is needed. Parents of adolescent boys also have different concerns about HPV vaccination than for adolescent girls, creating a need for unique health communication interventions to promote vaccine uptake among boys. Interventions also need to address the unique challenges of minority populations and populations for whom English is not the first language. A novel digital intervention will be produced and evaluated for its ability to improve HPV vaccine outcomes. Specifically, a mobile responsive web application ("mobile web app") will be created that performs similar to a mobile app but runs on a variety of computing platforms from personal desktop and laptop computers to the latest smart phones and tablet computers. Mobile web app content will be targeted to parents and adolescent boys aged 11-13 years. The specific aims are to: 1) carefully and systematically develop a mobile web app (BoyVac) for smart phones, tablet computers, and personal computers that will utilize Diffusion of Innovations principles to provide targeted information concerning HPV vaccine adoption to adolescent males and their parents, particularly minority adolescents and parents; 2) implement a comprehensive and rigorous test of the impact of the BoyVac mobile web app intervention on HPV vaccine adoption outcomes via a randomized efficacy trial (BoyVac v. usual and customary care); and 3) examine the dose-response relationships between mobile web app usage and vaccine outcomes within a components analysis. A group-randomized pretest-posttest controlled design will be implemented, recruiting 1800 pairs of parents and adolescent boys from 30 pediatric clinics (n=60 parents and boys per clinic). Parents will be surveyed at baseline, a 3-month follow-up, and a 9-month follow-up and records HPV vaccination adoption for the boys will be obtained from the clinics' medical records at the 9-month follow-up. Analyses will test the hypotheses that 1) more 11-13 year old boys in the intervention group (BoyVac mobile web app) will adopt the HPV vaccine than boys in the usual and customary care comparison group and 2) adoption of HPV vaccine will be mediated by improvements in theoretical mediators among parents in the intervention compared to the usual and customary care comparison group.


Recruitment information / eligibility

Status Completed
Enrollment 432
Est. completion date June 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 11 Years and older
Eligibility Inclusion Criteria: Adolescent boys: 1. being male 2. being 11-13 years old 3. being a patient at a participating University of New Mexico (UNM) Hospital's Envision pediatric practice 4. parental consent for testing, and 5. child assent for testing Parents/Guardians: 1. being a parent/guardian of an eligible and participating 11-13 year old boy 2. demonstrated ability to comprehend study requirements, and 3. providing informed consent for oneself and assent for their youth's participation Exclusion Criteria: Adolescent boys: 1. another immediate family member is participating in the project (i.e., a sibling) 2. the participant has already received any or all doses for the HPV vaccine, or 3. the participant refuses to assent. Parents/Guardians: 1. under the age of 18, or 2. another immediate family member is participating in the project (i.e., another parent).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Web App Intervention Group
All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
Usual Customary Care Group
Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.

Locations

Country Name City State
United States University of New Mexico Albuquerque New Mexico
United States Klein Buendel, Inc. Golden Colorado
United States Indiana University Indianapolis Indiana

Sponsors (4)

Lead Sponsor Collaborator
Klein Buendel, Inc. Indiana University, National Cancer Institute (NCI), University of New Mexico

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vaccine Initiation Vaccine initiation - whether or not each boy received the HPV vaccine and the date of administration. Number of participants who received at least 1 dose. 1 Month
Primary Vaccine Adherence Vaccine Adherence - whether participants adhered to the three-dose course of the HPV vaccination or not. 2nd dose and date received. Number of participants who received at least 2 doses. 2 Months
Primary Vaccine Adherence Vaccine Adherence - whether participants adhered to the three-dose course of the HPV vaccination or not. 3rd dose and date received. Number of participants who received the 3 doses. 4 months
Secondary Attitudes towards vaccination in general Quantitative research in the form of an online survey will be conducted to examine attitudes towards vaccinations in general Baseline, 3-month follow-up, and 9-month follow-up
Secondary Attitudes towards the HPV vaccine Quantitative research in the form of an online survey will be conducted to examine attitudes towards the HPV vaccine Baseline, 3-month follow-up, and 9-month follow-up
Secondary Perception of risk due to HPV and not being vaccinated Quantitative research in the form of an online survey will be conducted to examine the perception of risk due to HPV and not being vaccinated. Baseline, 3-month follow-up, and 9-month follow-up
Secondary Perception of negative and positive consequences associated with HPV vaccination Quantitative research in the form of an online survey will be conducted to examine the perception of negative and positive consequences associated with HPV vaccination. Baseline, 3-month follow-up, and 9-month follow-up
Secondary Self-efficacy to make informed decisions about HPV vaccination Quantitative research in the form of an online survey will be conducted to examine the self-efficacy to make informed decisions about HPV vaccination Baseline, 3-month follow-up, and 9-month follow-up
Secondary HPV knowledge Quantitative research in the form of an online survey will be conducted to examine the participant's knowledge about HPV Baseline, 3-month follow-up, and 9-month follow-up
Secondary Spousal support and social normative and cultural perceptions of receiving the HPV vaccination Quantitative research in the form of an online survey will be conducted to examine the spousal support and social normative and cultural perceptions of receiving the HPV vaccination. Baseline, 3-month follow-up, and 9-month follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT01105000 - Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity
Recruiting NCT06147388 - Regression of Cervical Precancerous Lesions and Associated Risk Factors
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Recruiting NCT06109870 - Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening N/A
Completed NCT03082950 - HPV Infections, Cancer of the Vulva and Therapeutical Success
Recruiting NCT01512784 - Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults Phase 3
Recruiting NCT05363709 - BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients Phase 2
Completed NCT01231945 - Low-Cost Molecular Cervical Cancer Screening Study N/A
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting NCT05996016 - Gut and Vaginal Microbiota Profile Study for HIV Women
Completed NCT05907187 - Research in Ethno-Medicine and Education (REMED) N/A
Completed NCT05616767 - Prevention and Screening for Early Detection of HPV-related Cancers in Gay and Bisexual Men in Tanzania N/A
Completed NCT02247999 - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Terminated NCT01468636 - A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Phase 4
Active, not recruiting NCT04965792 - Post-treatment Surveillance in HPV+ Oropharyngeal SCC
Active, not recruiting NCT05006833 - Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness N/A
Enrolling by invitation NCT06120205 - SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening N/A
Recruiting NCT05208710 - PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers Early Phase 1
Completed NCT05462249 - Impact of Catch-up HPV Vaccination